Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and ...

Related Keywords

Foster City ,California ,United States ,San Diego ,Qing Dong ,Stephen Kaldor ,Chris Lemasters ,Flavius Martin ,Orbimed Advisors ,Nasdaq ,Gilead Sciences Inc ,Exchange Commission ,Gilead Sciences ,Xinthera Provides Gilead ,Precision Small Molecules Focused ,Executive Vice President ,Gene Hung ,Foresite Capital ,